$0.80
3.92% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US8112921015
Symbol
SCYX
Sector
Industry

SCYNEXIS, Inc. Stock price

$0.80
-0.12 13.11% 1M
-0.38 32.25% 6M
-0.41 33.93% YTD
-1.82 69.49% 1Y
-1.32 62.29% 3Y
-7.15 89.94% 5Y
-87.00 99.09% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.03 3.92%
ISIN
US8112921015
Symbol
SCYX
Sector
Industry

Key metrics

Market capitalization $31.19m
Enterprise Value $-7.36m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -2.80
P/S ratio (TTM) P/S ratio 11.86
P/B ratio (TTM) P/B ratio 0.62
Revenue growth (TTM) Revenue growth -98.13%
Revenue (TTM) Revenue $2.63m
EBIT (operating result TTM) EBIT $-36.22m
Cash position $41.04m
EPS (TTM) EPS $-0.58
P/E forward negative
P/S forward 1.66
EV/Sales forward negative
Short interest 2.09%
Show more

Is SCYNEXIS, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

SCYNEXIS, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a SCYNEXIS, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a SCYNEXIS, Inc. forecast:

Buy
100%

Financial data from SCYNEXIS, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.63 2.63
98% 98%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
23% 23%
552%
- Research and Development Expense 24 24
22% 22%
925%
-36 -36
149% 149%
-1,377%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
149% 149%
-1,377%
Net Profit -27 -27
127% 127%
-1,030%

In millions USD.

Don't miss a Thing! We will send you all news about SCYNEXIS, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCYNEXIS, Inc. Stock News

Neutral
GlobeNewsWire
2 months ago
JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2024.

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Head office United States
CEO David Gonzalez
Employees 28
Founded 1999
Website www.scynexis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today